WVU cancer researcher and Assistant Professor of Pharmaceutical Sciences Wei Du, MD, PhD, teamed up with researchers from Cincinnati Children’s Hospital Medical Center to focus on improving outcomes and reducing side effects of traditional stem cell transplant. Their work was recently published in Leukemia, one of the top journals in hematology.

The studies identify an innovative drug that targets Cdc42, a member of one of the Rho GTPase family, which increases bone marrow accessibility and therefore improves stem cell transplant outcome. This project is an extension of previous research in the field of Rho GTPase family in hematopoiesis and is intended to address the urgent and important need for stem cell transplantation. Dr. Du’s work offers a novel preparative regimen for stem cell transplantation in treating bone marrow failure and other blood diseases. They are currently working on establishing improved methods for blood stem cell harvest and transplantation that could significantly impact future stem cell therapies for patients with leukemia and other blood cancers.

A non-myeloablative conditioning approach for long-term engraftment of human and mouse hematopoietic stem cells.

Rational identification of a Cdc42 inhibitor presents a new regimen for long-term hematopoietic stem cell mobilization

In the News:

Two Studies Describe Improved Approach to Bone Marrow Transplant - Cincinnati Children's Newsroom